サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1390930

急性興奮・攻撃性治療の世界市場レポート 2024年

Acute Agitation And Aggression Treatment Market Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
急性興奮・攻撃性治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

2023年の急性興奮・攻撃性治療市場で最大の地域は北米です。アジア太平洋は予測期間中に最も急成長する地域と予想されます。急性興奮・攻撃性治療レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 急性興奮・攻撃性治療市場の特徴

第3章 急性興奮・攻撃性治療市場の動向と戦略

第4章 急性興奮・攻撃性治療市場 - マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の急性興奮・攻撃性治療市場規模と成長

  • 世界の急性興奮・攻撃性治療市場の促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の急性興奮・攻撃性治療の市場規模実績と成長、2018年～2023年
  • 世界の急性興奮・攻撃性治療市場規模と成長予測、2023年～2028年、2033年まで

第6章 急性興奮・攻撃性治療市場セグメンテーション

  • 世界の急性興奮・攻撃性治療市場、治療アプローチ別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 行動的アプローチ
  • 環境への介入
  • 薬理学的アプローチ
  • 世界の急性興奮・攻撃性治療市場、薬剤クラス別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 抗精神病薬
  • ベンゾジアゼピン系
  • 他の薬剤クラス
  • 世界の急性興奮・攻撃性治療市場、投与経路別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 経口
  • 筋肉内
  • 他の投与経路
  • 世界の急性興奮・攻撃性治療市場、適応症別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 統合失調症
  • 認知症
  • 双極性障害
  • うつ
  • 薬物誘発性の興奮と攻撃性
  • アルコール離脱
  • その他の適応症
  • 世界の急性興奮・攻撃性治療市場、エンドユーザー別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 病院と外来手術センター
  • 精神科医療施設
  • その他のエンドユーザー

第7章 急性興奮・攻撃性治療市場の地域および国分析

  • 世界の急性興奮・攻撃性治療市場、地域別、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 世界の急性興奮・攻撃性治療市場、国別、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで

第8章 アジア太平洋の急性興奮・攻撃性治療市場

  • 概要
  • 地域情報、COVID-19の影響、市場情報、背景情報、政府の取り組み、規制、規制機関、主要団体、課税額、法人税構造、投資、主要企業
  • 治療アプローチ別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 薬剤クラス別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • エンドユーザー別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで

第9章 中国の急性興奮・攻撃性治療市場

第10章 インドの急性興奮・攻撃性治療市場

第11章 日本の急性興奮・攻撃性治療市場

第12章 オーストラリアの急性興奮・攻撃性治療市場

第13章 インドネシアの急性興奮・攻撃性治療市場

第14章 韓国の急性興奮・攻撃性治療市場

第15章 西欧の急性興奮・攻撃性治療市場

  • 概要
  • 治療アプローチ別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 薬剤クラス別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • エンドユーザー別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで

第16章 英国の急性興奮・攻撃性治療市場

第17章 ドイツの急性興奮・攻撃性治療市場

第18章 フランスの急性興奮・攻撃性治療市場

第19章 イタリアの急性興奮・攻撃性治療市場

第20章 スペインの急性興奮・攻撃性治療市場

第21章 東欧の急性興奮・攻撃性治療市場

  • 概要
  • 治療アプローチ別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 薬剤クラス別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • エンドユーザー別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで

第22章 ロシアの急性興奮・攻撃性治療市場

第23章 北米の急性興奮・攻撃性治療市場

  • 概要
  • 治療アプローチ別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 薬剤クラス別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • エンドユーザー別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで

第24章 米国の急性興奮・攻撃性治療市場

第25章 カナダの急性興奮・攻撃性治療市場

第26章 南米の急性興奮・攻撃性治療市場

  • 概要
  • 治療アプローチ別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 薬剤クラス別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • エンドユーザー別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで

第27章 ブラジルの急性興奮・攻撃性治療市場

第28章 中東の急性興奮・攻撃性治療市場

  • 概要
  • 治療アプローチ別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 薬剤クラス別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • エンドユーザー別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで

第29章 アフリカの急性興奮・攻撃性治療市場

  • 概要
  • 治療アプローチ別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • 薬剤クラス別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで
  • エンドユーザー別のセグメンテーション、実績および予測、2018年～2023年、2023年～2028年まで、2033年まで

第30章 急性興奮・攻撃性治療市場の競合情勢と企業プロファイル

  • 急性興奮・攻撃性治療市場の競合情勢
  • 急性興奮・攻撃性治療市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Pvt Ltd.
    • F Hoffmann-La Roche Ltd
    • AbbVie Inc.
    • Novartis AG

第31章 世界の急性興奮・攻撃性治療市場の競合ベンチマーキング

第32章 世界の急性興奮・攻撃性治療市場の競合ダッシュボード

第33章 急性興奮・攻撃性治療市場における主要な合併および買収

第34章 急性興奮・攻撃性治療市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r9290

“Acute Agitation And Aggression Treatment Market Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute agitation and aggression treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute agitation and aggression treatment market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The acute agitation and aggression treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Treatment Approach: Behavioral Approaches; Environmental Interventions; Pharmacologic Approaches
  • 2) By Drug Class: Anti-Psychotics; Benzodiazepines; Other Drug Classes
  • 3) By Route of Administration: Oral; Intramuscular; Other Routes of Administrations
  • 4) By Indication: Schizophrenia; Dementia; Bipolar Disorder; Depression; Drug-Induced Agitation And Aggression; Alcohol Withdrawal; Other Indications
  • 5) By End User: Hospitals And Ambulatory Surgical Centers; Psychiatric Care Facilities; Other End Users
  • Companies Mentioned: Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd, AstraZeneca PLC, Ono Pharmaceutical Co Ltd, Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc, Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc;;;;
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Treatment for acute agitation and aggression addresses the sudden onset of restlessness, irritability, and hostility in patients, aiming to manage and alleviate these symptoms. Such behaviors can be manifestations of underlying conditions like psychiatric disorders, neurological issues, or substance use or withdrawal effects.

The primary methods for managing acute agitation and aggression encompass behavioral, environmental, and pharmacological approaches. The behavioral approach involves the scientific study of observable behavior and its environmental triggers, emphasizing psychological perspectives. Pharmacologic approaches often employ diverse drugs, such as anti-psychotics, benzodiazepines, and others, administered through various routes like oral or intramuscular. These treatments target conditions such as schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation, alcohol withdrawal, and more. They are utilized across various settings, including hospitals, ambulatory surgical centers, psychiatric care facilities, and other healthcare environments.

The acute agitation and aggression treatment market research report is one of a series of new reports from The Business Research Company that provides acute agitation and aggression treatment market statistics, including acute agitation and aggression treatment industry global market size, regional shares, competitors with acute agitation and aggression treatment market share, detailed acute agitation and aggression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acute agitation and aggression treatment industry. This acute agitation and aggression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute agitation & aggression treatment market size has grown strongly in recent years. It will grow from $5.4 in 2023 to $5.72 in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth observed during the historic period can be attributed to several factors, including advancements in pharmacology, increased emphasis on clinical research, regulatory approvals for new treatments, a higher prevalence of cases related to acute agitation and aggression, and an enhanced awareness concerning mental health.

The acute agitation & aggression treatment market size is expected to see strong growth in the next few years. It will grow to $7.23 in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period can be linked to several key factors such as the expanding aging population, increasing development of healthcare infrastructure, a rise in investments within the pharmaceutical industry, the escalation of home-based care services, and the overall growth in disposable income. Major trends expected during this forecast period encompass non-pharmacological interventions, the advent of precision medicine, the integration of AI and predictive analytics, the emphasis on community-based support, and increased collaboration within the industry.

The anticipated expansion of the acute agitation and aggression treatment market is closely tied to several significant factors. Firstly, the increasing incidence of dementia is expected to be a driving force. Dementia, a condition marked by cognitive impairments and an inability to perform daily tasks, often leads to symptoms like agitation and restlessness. Effective treatment is crucial in managing these symptoms, improving the patient's quality of life, and addressing the root causes of agitation. For instance, according to data from the Australian Institute of Health and Welfare in February 2023, Australia is expected to see a substantial rise in dementia cases, reaching 849,300 by 2058, highlighting the need for treatments in this area.

The burden of mental illness is on the rise, further fueling the growth of the acute agitation and aggression treatment market. Mental illnesses impact various aspects of an individual's well-being, necessitating treatment for disruptive and potentially harmful behaviors. This treatment ensures both the patient's safety and the well-being of those around them. As per data from the NHS Business Services Authority in July 2021, there was a notable increase in the prescription of antidepressant medications in response to mental health challenges, emphasizing the growing demand for treatments in the mental health domain.

Major companies within the acute agitation and aggression treatment market are actively engaged in innovative product development and approvals, exemplified by IGALMI (dexmedetomidine). IGALMI, a sublingual film, has received FDA approval and offers a new treatment avenue for individuals dealing with agitation associated with schizophrenia or bipolar disorders. Developed by BioXcel Therapeutics Inc. in April 2022, this fast-acting and short-duration medication represents an advancement in addressing severe or life-threatening conditions. These developments contribute to the evolving landscape of treatments within the market.

Major companies operating in the acute agitation and aggression treatment market are focusing on developing innovative products, such as a generic version of Zyprexa, to address the needs of patients. Generic Zyprexa is a version of the brand-name drug Zyprexa, which contains the active ingredient olanzapine and is used to treat psychotic conditions. For instance, in September 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, launched a generic version of Zyprexa. This atypical antipsychotic drug is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania.

In April 2023, SK Capital Partners LP, a private investment firm based in the United States, completed the acquisition of Apotex Inc., a renowned Canada-based generic pharmaceutical company. The acquisition, for an undisclosed sum, represents a strategic move enabling SK Capital to broaden its presence within the generic pharmaceutical sector. Apotex's specialization in producing medications for treating acute agitation and aggression aligns with SK Capital's extended investment pursuits in the healthcare industry.

Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc

North America was the largest region in the acute agitation and aggression treatment market in 2023 . Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute agitation and aggression treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute agitation and aggression treatment market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The acute agitation and aggression treatment market includes revenues earned by entities by providing treatment with de-escalation techniques, psychosocial support, and medical evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute agitation and aggression treatment market also consists of sales of lorazepam, chlorpromazine, and quetiapine API, droperidol, olanzapine, and ziprasidone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Acute Agitation And Aggression Treatment Market Characteristics

3. Acute Agitation And Aggression Treatment Market Trends And Strategies

4. Acute Agitation And Aggression Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Acute Agitation And Aggression Treatment Market Size and Growth

  • 5.1. Global Acute Agitation And Aggression Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Acute Agitation And Aggression Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Acute Agitation And Aggression Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Acute Agitation And Aggression Treatment Market Segmentation

  • 6.1. Global Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Behavioral Approaches
  • Environmental Interventions
  • Pharmacologic Approaches
  • 6.2. Global Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Anti-Psychotics
  • Benzodiazepines
  • Other Drug Classes
  • 6.3. Global Acute Agitation And Aggression Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Intramuscular
  • Other Routes of Administrations
  • 6.4. Global Acute Agitation And Aggression Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Schizophrenia
  • Dementia
  • Bipolar Disorder
  • Depression
  • Drug-Induced Agitation And Aggression
  • Alcohol Withdrawal
  • Other Indications
  • 6.5. Global Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals And Ambulatory Surgical Centers
  • Psychiatric Care Facilities
  • Other End Users

7. Acute Agitation And Aggression Treatment Market Regional And Country Analysis

  • 7.1. Global Acute Agitation And Aggression Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Acute Agitation And Aggression Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Acute Agitation And Aggression Treatment Market

  • 8.1. Asia-Pacific Acute Agitation And Aggression Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Acute Agitation And Aggression Treatment Market

  • 9.1. China Acute Agitation And Aggression Treatment Market Overview
  • 9.2. China Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Acute Agitation And Aggression Treatment Market

  • 10.1. India Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Acute Agitation And Aggression Treatment Market

  • 11.1. Japan Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Acute Agitation And Aggression Treatment Market

  • 12.1. Australia Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Acute Agitation And Aggression Treatment Market

  • 13.1. Indonesia Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Acute Agitation And Aggression Treatment Market

  • 14.1. South Korea Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Acute Agitation And Aggression Treatment Market

  • 15.1. Western Europe Acute Agitation And Aggression Treatment Market Overview
  • 15.2. Western Europe Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Acute Agitation And Aggression Treatment Market

  • 16.1. UK Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Acute Agitation And Aggression Treatment Market

  • 17.1. Germany Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Acute Agitation And Aggression Treatment Market

  • 18.5. France Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.6. France Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.7. France Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Acute Agitation And Aggression Treatment Market

  • 19.9. Italy Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Acute Agitation And Aggression Treatment Market

  • 20.13. Spain Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Acute Agitation And Aggression Treatment Market

  • 21.1. Eastern Europe Acute Agitation And Aggression Treatment Market Overview
  • 21.2. Eastern Europe Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Acute Agitation And Aggression Treatment Market

  • 22.1. Russia Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Acute Agitation And Aggression Treatment Market

  • 23.1. North America Acute Agitation And Aggression Treatment Market Overview
  • 23.2. North America Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Acute Agitation And Aggression Treatment Market

  • 24.1. USA Acute Agitation And Aggression Treatment Market Overview
  • 24.2. USA Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Acute Agitation And Aggression Treatment Market

  • 25.1. Canada Acute Agitation And Aggression Treatment Market Overview
  • 25.2. Canada Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Acute Agitation And Aggression Treatment Market

  • 26.1. South America Acute Agitation And Aggression Treatment Market Overview
  • 26.2. South America Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Acute Agitation And Aggression Treatment Market

  • 27.1. Brazil Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Acute Agitation And Aggression Treatment Market

  • 28.1. Middle East Acute Agitation And Aggression Treatment Market Overview
  • 28.2. Middle East Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Acute Agitation And Aggression Treatment Market

  • 29.1. Africa Acute Agitation And Aggression Treatment Market Overview
  • 29.2. Africa Acute Agitation And Aggression Treatment Market, Segmentation By Treatment Approach, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Acute Agitation And Aggression Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Acute Agitation And Aggression Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Acute Agitation And Aggression Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Acute Agitation And Aggression Treatment Market Competitive Landscape
  • 30.2. Acute Agitation And Aggression Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Pvt Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F Hoffmann-La Roche Ltd
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Acute Agitation And Aggression Treatment Market Competitive Benchmarking

32. Global Acute Agitation And Aggression Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Acute Agitation And Aggression Treatment Market

34. Acute Agitation And Aggression Treatment Market Future Outlook and Potential Analysis

  • 34.1 Acute Agitation And Aggression Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Acute Agitation And Aggression Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Acute Agitation And Aggression Treatment Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer